NY-DC-ADMINISTRATION
DC Administration Services, Inc. has today announced the composition of five regional Determinations Committees (DCs), effective from April 27, 2024.
Voting Dealers (for all regions): |
Voting Non-Dealers (for all regions): |
|||
Bank of America N.A. |
Citadel LLC |
|||
Barclays Bank plc |
Elliott Management Corporation |
|||
BNP Paribas |
Pacific Investment Management Company LLC |
|||
Citibank, N.A. |
|
|||
Deutsche Bank AG |
|
|||
Goldman Sachs International |
|
|||
JPMorgan Chase Bank, N.A. |
|
|||
|
|
|||
Voting Dealer for the Americas, EMEA, AEJ, and Japan Determination Committees: |
||||
Mizuho Securities Co., Ltd. |
||||
The process for selecting DC members is specified in the DC rules. The DC rules, along with more information about the Determinations Committees and what they do can be found at the Determinations Committees website: https://www.cdsdeterminationscommittees.org/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240328441002/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sirius Therapeutics Announces Promising Phase I Clinical Data from Its Factor XI siRNA, a Long-Acting Next-Generation Anticoagulant for Thromboembolic Disorders10.12.2024 05:00:00 CET | Press release
Data presented at American Society of Hematology annual meeting Sirius Therapeutics today announced promising preliminary data from its Phase 1 first-in-human clinical trial of SRSD107, a next generation siRNA therapeutics under clinical development for the prevention and treatment of thromboembolic disorders, such as myocardial infarction, ischemic stroke, and venous thromboembolism. The trial data were presented during a poster session at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, held in San Diego, CA. SRSD107 is designed to inhibit Factor XI (FXI), a protein in the coagulation pathway that has shown potential to reduce thrombosis without significantly increasing the risk of bleeding, a major liability of current drugs. “In this trial, SRSD107 was safe and well tolerated, with pharmacokinetic parameters consistent with a typical siRNA product,” said Dr. Patrick Yue, Sirius’ Chief Medical Officer. “We are encouraged by the marked, prolonged reduction
Mori Memorial Foundation Issues GPCI–2024 and GPCI–Financial Centers Reports:10.12.2024 04:00:00 CET | Press release
— Post-Pandemic Economic Recovery and International Tourism Expansion Impact Rankings — The Mori Memorial Foundation’s Institute for Urban Strategies, a research body established by Mori Building, Tokyo’s leading urban landscape developer, today released its Global Power City Index (GPCI) 2024 report on the overall strength of the world’s 48 major cities. For the second time, the report additionally includes the 'GPCI–Financial Centers' index. This index reflects the growing importance of measures taken by major cities to enhance their status as international financial centers, capturing changes in their financial and business environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241209714811/en/ The 48 major cities evaluated in Mori Memorial Foundation’s GPCI–2024 Report (Graphic: Business Wire) More than 18 months have elapsed since the World Health Organization declared an end to the COVID-19 pandemic in May 2023.
BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets10.12.2024 02:30:00 CET | Press release
5-year follow-up from SEQUOIA study demonstrated treatment with BRUKINSA reduced the risk of progression or death by 71% compared to bendamustine-rituximab in patients with treatment-naïve CLL, further solidifying its position as the leader in new patient starts in both frontline and relapsed/refractory (R/R) CLL with the broadest label of any BTK inhibitorAt a median follow-up of 1.5 years, promising data from the 320 mg expansion cohort of phase 1/1b study shows no progression in patients with treatment-naïve CLL treated with sonrotoclax, a next-generation BCL2 inhibitor, in combination with BRUKINSA highlighting the potential of this fixed-duration, oral-only combination as a best-in-disease optionData for BTK degrader BGB-16673 from phase 1/2 study highlight its potential in both treatment-resistant CLL and other B-cell malignancies representing high unmet needs BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that plans to change its name to BeOne
Material Receives Splash Award for Outstanding Drupal Website10.12.2024 02:00:00 CET | Press release
– Exceptional client work with INSEAD demonstrates noteworthy innovation and impact in digital engagement solutions – Material, a leading insights, marketing and technology company, is pleased to announce it is the recipient of the Splash Award in the “Education” category for work with INSEAD – The Business School for the World® and runner-up in the “Corporate” category for work with Stuff Limited. The first-ever DrupalCon Singapore Splash Awards celebrate outstanding websites and digital experiences built with Drupal, highlighting the creativity, technical excellence and innovative solutions agencies and developers bring to diverse industries and challenges. For the award-winning “Education” work, Material partnered with INSEAD to enhance the school’s overall digital presence, improve engagement and strengthen brand identity, aligning technology with business strategy to drive growth and success. Leveraging the latest Drupal technology, Material helped INSEAD increase conversion and r
Bardstown Bourbon Company and Brindiamo Expand Relationship with First-of-its-kind Barrel Leasing Program9.12.2024 20:21:00 CET | Press release
Bardstown Bourbon Company, the leading custom American whiskey distiller and Brindiamo, the global leader in sourcing bulk whiskey, today announced an exclusive relationship to provide a market-leading barrel leasing program for whiskey brand contract distillation customers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241209024956/en/ Bardstown Bourbon Company, the leading custom American whiskey distiller and Brindiamo, the global leader in sourcing bulk whiskey, will launch an exclusive barrel leasing program -- a timely, tailored solution for non-distilling brands. Roughly one-third of the cost of a new fill barrel is tied up in the wood used to make the barrel. This program allows brands to simplify this significant upfront expense into manageable monthly payments, offering customers the flexibility to plan for tomorrow while maintaining the cashflow to support their needs today. (Photo: Business Wire) As the whiskey
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom